Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience has announced that its drug SAT-3247, aimed at treating the rare genetic disorder Duchenne muscular dystrophy (DMD), received Rare Pediatric Disease and Orphan Drug Designations from the U.S. FDA. These designations underscore the significance of SAT-3247 as a potential game-changer for pediatric DMD patients, with a Phase 1 clinical trial expected to commence in Q3 2024.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
